Devin Barich

Devin Barich supports the Centers for Disease Control and Prevention’s Office of Acquisition Services in managing critical procurement activities that enable public health response and scientific advancement. Responsible for executing complex acquisitions in support of laboratory diagnostics, biomedical research, and data-driven surveillance systems, Barich ensures alignment with CDC’s mission to detect, respond to, and mitigate emerging health threats. Their work primarily involves procuring high-complexity scientific equipment, in-vitro diagnostic products, and biotechnology research services, often under time-sensitive conditions to support national health emergencies. Barich maintains consistent working relationships with key industry partners including General Dynamics Information Technology, GlaxoSmithKline, MRIGLOBAL, Cepheid, and the New York City Health & Hospitals Corp. These collaborations reflect a focus on mission-critical suppliers with proven capabilities in diagnostic instrumentation, biological product development, and advanced data analytics for epidemiological modeling. The procurement approach emphasizes technical rigor, regulatory compliance, and vendor reliability, prioritizing contractors with established track records in federal health and life sciences contracting. Set-aside preferences indicate a strong orientation toward open competition, with 90.9% of acquisitions conducted without socioeconomic set-asides. The remaining 9.1% are awarded under Total Small Business Set-Aside authorities, demonstrating a measured but intentional commitment to small business participation without compromising mission readiness. This pattern reflects a strategic balance between leveraging large-scale industrial capacity and fostering innovation from qualified small entities. The procurement portfolio is heavily concentrated in NAICS 334516 (Analytical Laboratory Instrument Manufacturing) and 325413 (In-Vitro Diagnostic Substance Manufacturing), underscoring deep technical expertise in diagnostic systems, molecular testing platforms, and laboratory automation. Additional focus areas include biological product manufacturing and biotechnology R&D, reflecting a specialized domain knowledge in infectious disease detection, clinical diagnostics, and public health laboratory infrastructure modernization.